NKTR Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 24.89% compared to Nektar Therapeutics's net margin of 16.9%. Nektar Therapeutics's return on equity of -133.07% beat Corcept Therapeutics's return on equity of 23.78%.

Nektar Therapeutics has a consensus price target of $4.92, signalling upside risk potential of 671%. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 105.85%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.

Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $29.2M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Nektar Therapeutics's net income of $7.3M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 56.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.33x versus 11.70x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 24.89% compared to Nektar Therapeutics's net margin of 39.44%. Nektar Therapeutics's return on equity of -133.07% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Nektar Therapeutics has a consensus price target of $4.92, signalling upside risk potential of 671%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 45.82%. Given that Nektar Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Catalyst Pharmaceuticals.

Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $29.2M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Nektar Therapeutics's net income of $7.3M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 17.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.33x versus 5.90x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 24.89% compared to Nektar Therapeutics's net margin of 24.22%. Nektar Therapeutics's return on equity of -133.07% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Nektar Therapeutics has a consensus price target of $4.92, signalling upside risk potential of 671%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $893.09 which suggests that it could grow by 60.08%. Given that Nektar Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Regeneron Pharmaceuticals.

Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $29.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Nektar Therapeutics's net income of $7.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.33x versus 4.52x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of 24.89% compared to Nektar Therapeutics's net margin of -86.29%. Nektar Therapeutics's return on equity of -133.07% beat Xencor's return on equity of -35.99%.

Nektar Therapeutics has a consensus price target of $4.92, signalling upside risk potential of 671%. On the other hand Xencor has an analysts' consensus of $30.30 which suggests that it could grow by 217.61%. Given that Nektar Therapeutics has higher upside potential than Xencor, analysts believe Nektar Therapeutics is more attractive than Xencor.

Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Xencor has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.041%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $29.2M, which are smaller than Xencor quarterly revenues of $52.8M. Nektar Therapeutics's net income of $7.3M is higher than Xencor's net income of -$45.6M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.33x versus 5.62x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.